Form 4: Assembly Biosciences Director Michael Houghton Granted 3,500 Stock Options

Assembly Biosciences, Inc. Director Michael Houghton was granted 3,500 stock options with an exercise price of $15.81, aligning his interests with shareholder value.

Summary

• Michael Houghton, a Director of ASSEMBLY BIOSCIENCES, INC. (ASMB), was granted 3,500 stock options.
• The transaction date for this grant was June 5, 2025.
• Each stock option has an exercise price of $15.81.
• The options will vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, assuming continuous service.
• The expiration date for these stock options is June 5, 2035.
• Following this transaction, Michael Houghton beneficially owns 3,500 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued alignment of a director's interests with the company's long-term performance through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The grant of stock options to a director aligns management's and the board's interests with those of the shareholders, as the options gain value if the stock price increases.
• This is a standard form of compensation, indicating continued commitment from the director to the company's performance.

Future Outlook

The stock options are set to vest upon the earlier of June 5, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, contingent on Michael Houghton's continuous service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of executive and board compensation packages designed to incentivize long-term performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of director compensation across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's financial interests with shareholder value creation, as the options become more valuable if the company's stock price increases.

Next Steps

• The stock options will vest on June 5, 2026, or at the Issuer's 2026 annual meeting of stockholders, whichever comes first, subject to continuous service.

Key Dates

Keywords

Assembly Biosciences, ASMB, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Beneficial Ownership